Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Original Article

Outcome of a Hepatitis C Outbreak Among Patients in a Pain Management Clinic

Authors: Javid Fazili, Sue Mallonee, William M. Tierney, Teddy F. Bader, Arun K. Sachdev, Philip C. Bird, Robert D. Schmidt, Sikander A. Mesiya, Charles L. Lackey

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Abstract

Background and Aims

The aims of this study are to evaluate the natural history and response to therapy of patients following a hepatitis C outbreak in a pain management clinic.

Methods

A retrospective cohort study was conducted on patients who acquired hepatitis C virus (HCV) at a pain management clinic. Medical records were retrospectively reviewed for 77% of patients with hepatitis C included in the outbreak to obtain data regarding laboratory results, treatment, and outcomes. Chi-square, Fisher’s exact, and Student’s t-test were used to determine variables that were significantly associated with spontaneous clearance or sustained virologic response to therapy.

Results

Fifty Caucasian patients (31 women, 19 men; mean age 52 years) were included. Eleven of 50 (22%) patients cleared HCV spontaneously (clearers). The mean age of clearers was 47 years as compared with 57 years for nonclearers (P = 0.04). Liver biopsies were obtained by treating gastroenterologists in 31 patients with mean grade and stage of 2.1 and 1.7, respectively. Gastroenterologists treated 31 of 39 patients with pegylated interferon and ribavirin after a median of 354 (range 140-1,099) days post exposure. Sustained viral response (SVR) was observed in 65% (20/31) on an intention-to-treat basis. In patients who completed therapy, 91% (20/22) achieved SVR. Age, sex, weight, pretreatment alanine aminotransferase (ALT), and histologic parameters were not associated with SVR.

Conclusions

In this large cohort of US immunocompetent patients with recent HCV infection, 22% resolved spontaneously. Younger age was the only predictor of spontaneous clearance. In patients with early chronic HCV, 65% achieved SVR.
Literature
1.
go back to reference World Health Organization. Hepatitis C update. Wkly Epidemiol Rec. 1999;74:425–427. World Health Organization. Hepatitis C update. Wkly Epidemiol Rec. 1999;74:425–427.
3.
go back to reference Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(suppl 1):9–16.CrossRefPubMed Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(suppl 1):9–16.CrossRefPubMed
4.
go back to reference Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Sem Liver Dis. 2000;20(1):17–35.CrossRef Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Sem Liver Dis. 2000;20(1):17–35.CrossRef
5.
go back to reference Arlic L, Fort M, Izopet J, et al. Study of host and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000;56:154–158.CrossRef Arlic L, Fort M, Izopet J, et al. Study of host and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000;56:154–158.CrossRef
6.
go back to reference Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29(3):908–914.CrossRefPubMed Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29(3):908–914.CrossRefPubMed
8.
go back to reference Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype lb) single-source outbreak in Germany: a 20-year multicenter study. Hepatology. 2000;32(1):91–96.CrossRefPubMed Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype lb) single-source outbreak in Germany: a 20-year multicenter study. Hepatology. 2000;32(1):91–96.CrossRefPubMed
9.
go back to reference Nomura H, Sou S, Tanimoto H, et al. Short-term Interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39(5):1213–1219.CrossRefPubMed Nomura H, Sou S, Tanimoto H, et al. Short-term Interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39(5):1213–1219.CrossRefPubMed
10.
go back to reference Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.CrossRefPubMed Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.CrossRefPubMed
11.
go back to reference Blackard JT, Shata MT, Shire NJ, et al. Acute hepatits C virus infection: a chronic problem. Hepatology. 2008;47(1):321–330.CrossRefPubMed Blackard JT, Shata MT, Shire NJ, et al. Acute hepatits C virus infection: a chronic problem. Hepatology. 2008;47(1):321–330.CrossRefPubMed
12.
go back to reference Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C, impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–638.CrossRefPubMed Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C, impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–638.CrossRefPubMed
13.
go back to reference Macedo G, Correia A, Ribeiro T. Antiviral treatment in acute hepatitis C. Hepatogastroenterology. 2003;50(52):1057–1059.PubMed Macedo G, Correia A, Ribeiro T. Antiviral treatment in acute hepatitis C. Hepatogastroenterology. 2003;50(52):1057–1059.PubMed
14.
go back to reference Larghi A, Zuin M, Crosignant A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.PubMed Larghi A, Zuin M, Crosignant A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.PubMed
15.
go back to reference Comstock RD, Mallonee S, Fox JL, et al. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. Infect Control Hosp Epidemiol. 2004;25:576–583.CrossRefPubMed Comstock RD, Mallonee S, Fox JL, et al. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. Infect Control Hosp Epidemiol. 2004;25:576–583.CrossRefPubMed
16.
go back to reference Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology. 2002;36:S195–S200.CrossRefPubMed Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology. 2002;36:S195–S200.CrossRefPubMed
17.
go back to reference Booth JCL, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001;49(suppl. 1):i1–i21.CrossRefPubMed Booth JCL, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001;49(suppl. 1):i1–i21.CrossRefPubMed
18.
go back to reference Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001;165(7):889–895.PubMed Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001;165(7):889–895.PubMed
19.
go back to reference Macedo de Oliveira A, Shite KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142:898–902.PubMed Macedo de Oliveira A, Shite KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142:898–902.PubMed
20.
go back to reference Furusyo N, Kubo N, Nakashima H, et al. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol. 2004;25:584–590.CrossRefPubMed Furusyo N, Kubo N, Nakashima H, et al. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol. 2004;25:584–590.CrossRefPubMed
21.
go back to reference Centers for Disease Control and Prevention. Transmission of hepatitis B and C virus in outpatient settings—New York, Oklahoma, Nebraska—2000-2002. MMWR. 2004;52(38):901–906. Centers for Disease Control and Prevention. Transmission of hepatitis B and C virus in outpatient settings—New York, Oklahoma, Nebraska—2000-2002. MMWR. 2004;52(38):901–906.
22.
go back to reference Centers for Disease Control and Prevention. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007. MMWR. 2008;57(19):513–517. Centers for Disease Control and Prevention. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007. MMWR. 2008;57(19):513–517.
23.
go back to reference Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35(2):104–113.CrossRefPubMed Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35(2):104–113.CrossRefPubMed
24.
go back to reference Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–1457.CrossRefPubMed Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–1457.CrossRefPubMed
25.
go back to reference Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.CrossRefPubMed Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.CrossRefPubMed
26.
go back to reference Fried MW, Shiffman ML, Reddy R, et al. Peg-interferon alfa-2a plus ribavirin from chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.CrossRefPubMed Fried MW, Shiffman ML, Reddy R, et al. Peg-interferon alfa-2a plus ribavirin from chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.CrossRefPubMed
27.
go back to reference Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–1672.CrossRefPubMed Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–1672.CrossRefPubMed
28.
go back to reference Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965.CrossRefPubMed Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965.CrossRefPubMed
Metadata
Title
Outcome of a Hepatitis C Outbreak Among Patients in a Pain Management Clinic
Authors
Javid Fazili
Sue Mallonee
William M. Tierney
Teddy F. Bader
Arun K. Sachdev
Philip C. Bird
Robert D. Schmidt
Sikander A. Mesiya
Charles L. Lackey
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1228-z

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine